Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398450 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00398450 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 12 participants.
The verdict
NCT00398450, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Interferon alfa may interfere with the growth of tumor cells. Giving azacitidine together with interferon alfa may be an effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects and best dose of azacitidine when given together with interferon alfa in treating patients with metastatic melanoma.
Interventions
- DRUG azacitidine
- BIOLOGICAL recombinant interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398450
The ClinicalTrials.gov registry entry for NCT00398450 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which azacitidine is the first listed.
NCT00398450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398450 about?
NCT00398450 is a clinical study titled "Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma". RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Interferon alfa may interfere with the growth of tumor cells. Giving azacitidine together with interferon alfa may be a...
What is the current status of trial NCT00398450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-02. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00398450?
The interventions under investigation include: azacitidine (DRUG), recombinant interferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00398450?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.